{"success":true,"data":{"pressRelease":{"id":"159693","rtpr_id":"nGNX5KWn32-20261002","ticker":"VERA","exchange":"NASDAQ","all_tickers":["VERA"],"title":"Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-10-02T20:05:00.158Z","article_body":"BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc.\n(Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation\nCommittee of the Board of Directors (Compensation Committee) of Vera\nTherapeutics granted inducement awards consisting of non-qualified stock\noptions to purchase 16,700 shares of Class A common stock and restricted stock\nunits (RSUs) underlying 8,350 shares of Class A common stock to five (5) new\nemployees under the Inducement Plan. The Compensation Committee approved the\nawards as an inducement material to the new employees’ employment in\naccordance with Nasdaq Listing Rule 5635(c)(4).\n\nEach stock option granted on September 29, 2026 has an exercise price per\nshare equal to $32.38, Vera Therapeutics’ closing trading price on September\n29, 2026. Each stock option will vest over four years, with 25% of the\nunderlying shares vesting on the first anniversary of the applicable vesting\ncommencement date and the balance of the underlying shares vesting monthly\nthereafter over 36 months, subject to the new employee’s continued service\nrelationship with Vera Therapeutics through the applicable vesting dates. Each\nof the RSU awards will vest over four years, with 25% of the underlying shares\nvesting on each anniversary of November 20, subject to the new employee’s\ncontinued service relationship with Vera Therapeutics through the applicable\nvesting dates. The awards are subject to the terms and conditions of the\nInducement Plan and the terms and conditions of an applicable award agreement\ncovering the grant.\n\nAbout Vera Therapeutics\nVera Therapeutics is a commercial-stage biotechnology company focused on the\npursuit of truth in science to transform medicine in autoimmune disease,\nstarting with the kidney. Vera Therapeutics’ flagship commercial product is\nTRUTAKNA(™) (atacicept-vymj), a B-cell activating factor (BAFF) and A\nproliferation-inducing ligand (APRIL) inhibitor. Vera Therapeutics is\nevaluating multiple diseases where the reduction of autoantibodies through\ninhibition of BAFF and APRIL may prove clinically meaningful. Vera\nTherapeutics was founded in 2016 and is based in Brisbane, California. To\nlearn more, visit www.veratx.com.\n\nFor more information, please contact:\n\nInvestor Contact:\nJoshua Qin\nVera Therapeutics 650-360-6978\nir@veratx.com\n\nMedia Contact:\nDebra Charlesworth Vera Therapeutics 415-854-8051\ncorporatecommunications@veratx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/25b71017-1f55-4adb-9d6a-17c2ba55b36e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5KWn32-20261002","title":"Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"VERA","created":"2026-10-02T20:05:00.158Z","tickers":["VERA"],"exchange":"NASDAQ","article_body":"BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc.\n(Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation\nCommittee of the Board of Directors (Compensation Committee) of Vera\nTherapeutics granted inducement awards consisting of non-qualified stock\noptions to purchase 16,700 shares of Class A common stock and restricted stock\nunits (RSUs) underlying 8,350 shares of Class A common stock to five (5) new\nemployees under the Inducement Plan. The Compensation Committee approved the\nawards as an inducement material to the new employees’ employment in\naccordance with Nasdaq Listing Rule 5635(c)(4).\n\nEach stock option granted on September 29, 2026 has an exercise price per\nshare equal to $32.38, Vera Therapeutics’ closing trading price on September\n29, 2026. Each stock option will vest over four years, with 25% of the\nunderlying shares vesting on the first anniversary of the applicable vesting\ncommencement date and the balance of the underlying shares vesting monthly\nthereafter over 36 months, subject to the new employee’s continued service\nrelationship with Vera Therapeutics through the applicable vesting dates. Each\nof the RSU awards will vest over four years, with 25% of the underlying shares\nvesting on each anniversary of November 20, subject to the new employee’s\ncontinued service relationship with Vera Therapeutics through the applicable\nvesting dates. The awards are subject to the terms and conditions of the\nInducement Plan and the terms and conditions of an applicable award agreement\ncovering the grant.\n\nAbout Vera Therapeutics\nVera Therapeutics is a commercial-stage biotechnology company focused on the\npursuit of truth in science to transform medicine in autoimmune disease,\nstarting with the kidney. Vera Therapeutics’ flagship commercial product is\nTRUTAKNA(™) (atacicept-vymj), a B-cell activating factor (BAFF) and A\nproliferation-inducing ligand (APRIL) inhibitor. Vera Therapeutics is\nevaluating multiple diseases where the reduction of autoantibodies through\ninhibition of BAFF and APRIL may prove clinically meaningful. Vera\nTherapeutics was founded in 2016 and is based in Brisbane, California. To\nlearn more, visit www.veratx.com.\n\nFor more information, please contact:\n\nInvestor Contact:\nJoshua Qin\nVera Therapeutics 650-360-6978\nir@veratx.com\n\nMedia Contact:\nDebra Charlesworth Vera Therapeutics 415-854-8051\ncorporatecommunications@veratx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/25b71017-1f55-4adb-9d6a-17c2ba55b36e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-02T20:05:00.208868499Z","server_sent_at_ms":1790971500208},"received_at":"2026-10-02T20:05:00.349Z","source_url":null},"analysis":{"id":"148290","press_release_id":"159693","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Vera Therapeutics granted inducement awards for five new employees: options on 16,700 Class A shares and RSUs on 8,350 shares under its Inducement Plan.\n\nOptions carry a $32.38 exercise price, equal to the September 29, 2026 close, with standard four-year vesting approved under Nasdaq Listing Rule 5635(c)(4).\n\nThis is routine equity-compensation housekeeping with no bearing on Vera's clinical or commercial outlook.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement grant boilerplate -- suppress."},"keyFigures":{"customDimensions":{"rsu_shares":8350,"new_employees":5,"exercise_price":32.38,"options_shares":16700}},"namedEntities":{"people":[{"name":"Joshua Qin","role":"Investor Contact"},{"name":"Debra Charlesworth","role":"Media Contact"}],"products":["TRUTAKNA (atacicept-vymj)"],"companies":[{"name":"Vera Therapeutics, Inc.","ticker":"VERA","relationship":"filer"}],"dollarAmounts":[{"amount":"$32.38","context":"stock option exercise price equal to Sept 29, 2026 closing price"}]},"materialImpact":{"score":1,"reasoning":"Routine Nasdaq 5635(c)(4) inducement grant boilerplate covering 16,700 options and 8,350 RSUs for five new employees. No strategic, financial, or regulatory content."},"tickerRelevance":{"others":[],"primary":"VERA"},"globalImportance":5,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap-biotech","eventGravity":"routine-inducement-grant","dilutiveImpact":"negligible"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Vera Therapeutics granted inducement awards for five new employees: options on 16,700 Class A shares and RSUs on 8,350 shares under its Inducement Plan.\n\nOptions carry a $32.38 exercise price, equal to the September 29, 2026 close, with standard four-year vesting approved under Nasdaq Listing Rule 5635(c)(4).\n\nThis is routine equity-compensation housekeeping with no bearing on Vera's clinical or commercial outlook.","key_figures":{"customDimensions":{"rsu_shares":8350,"new_employees":5,"exercise_price":32.38,"options_shares":16700}},"named_entities":{"people":[{"name":"Joshua Qin","role":"Investor Contact"},{"name":"Debra Charlesworth","role":"Media Contact"}],"products":["TRUTAKNA (atacicept-vymj)"],"companies":[{"name":"Vera Therapeutics, Inc.","ticker":"VERA","relationship":"filer"}],"dollarAmounts":[{"amount":"$32.38","context":"stock option exercise price equal to Sept 29, 2026 closing price"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-02T20:05:04.673Z","global_importance":5,"audience_relevance":8,"importance_components":{"tickerTier":"small-cap-biotech","eventGravity":"routine-inducement-grant","dilutiveImpact":"negligible"}},"durationMs":4302,"modelName":"glm-5.3-flashx"}}